瀘天化(000912.SZ):擬向進出口公司增資7000萬元
格隆匯12月16日丨瀘天化(000912.SZ)公佈,根據公司的發展實際,為了更好的推動公司全資子公司四川瀘天化進出口貿易有限公司(簡稱“進出口公司”)業務發展,奠定公司轉型發展的基礎;也為了降低進出口公司的資產負債率,增強對外融資能力、降低融資成本,公司擬對進出口公司追加投資7000萬元。
2022年12月16日公司召開了第七屆董事會第三十次會議,審議通過了《關於向四川瀘天化進出口貿易有限公司增資的議案》,同意使用自有資金向進出口公司增資7000萬元,該次增資完成後,進出口公司的註冊資本將由3000萬元變更為1億元,公司仍持有其100%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.